Randomized, Sequential, Open-Label Study to Evaluate the Efficacy of IDH Targeted/Non- Targeted Versus Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Latest Information Update: 22 May 2025
At a glance
- Drugs Azacitidine (Primary) ; Enasidenib (Primary) ; Ivosidenib (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms I-DATA Study
Most Recent Events
- 14 May 2025 Planned End Date changed from 30 Jun 2027 to 30 Jun 2029.
- 14 May 2025 Planned primary completion date changed from 30 Sep 2025 to 30 Sep 2027.
- 12 Dec 2023 Study design, presented at the 65th American Society of Hematology Annual Meeting and Exposition